Bleocel

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bleocel

Quick Facts

Property Description
Active ingredient Bleomycin sulfate
Form Lyophilized powder for injection
Pharmacological class Antineoplastic Antibiotic / Cytotoxic Agent
Common purpose Management of malignant neoplastic conditions
Origin Derived from Streptomyces verticillus (semi-natural)

Defining Bleocel: Type and Pharmacological Class

Bleocel is a highly potent, prescription-only cytotoxic medicine with the active ingredient Bleomycin sulfate. It is formally classified as an antineoplastic antibiotic and a cytotoxic agent. This classification establishes the drug's specialized purpose in targeting malignancy and inhibiting rapid cell growth. Bleomycin is clinically recognized for its inclusion in combination chemotherapy regimens for specific cancers. This makes it a foundational component in the management of certain neoplastic conditions, unlike broader cytotoxic agents used across multiple tumor types.

Composition, Origin, and Preparation Form

The active ingredient, Bleomycin, is a complex glycopeptide antibiotic that originates from the bacterium Streptomyces verticillus, classifying the substance as semi-natural in derivation. Bleocel is typically supplied as a sterile, lyophilized powder for injection, rather than a ready-to-use liquid. This format ensures the maximum stability and high-potency of the complex chemical structure until immediately before use. The powder requires precise reconstitution with a suitable sterile diluent, preparing the medicine for parenteral administration via injection, which requires administration in a supervised medical setting due to its specialized delivery needs.

High-Level Function in Malignancy Management

The central purpose of Bleocel is to disrupt the fundamental biological processes that sustain uncontrolled cellular growth. The substance achieves this by targeting the DNA within abnormal cells, causing direct damage and leading to DNA fragmentation. This interference is strategically effective during the cell division cycle, ultimately preventing the cell's ability to divide and multiply. Consequently, Bleocel functions as a critical, high-potency agent for achieving the sustained inhibition of cell proliferation, which is the primary objective in managing certain neoplastic conditions.

Regulatory References

  1. NIH LiverTox: Bleomycin

What side effects are possible with Bleocel?

Possible Side Effects and Safety Information

Bleocel's official safety profile, as documented in regulatory sources, is characterized by specific organ toxicities and time-related risks, consistent with its classification as a cytotoxic agent.

Officially Documented Adverse Reactions

The most significant safety concern listed in regulatory documents is Pulmonary Toxicity, which may manifest as interstitial pneumonitis progressing to potentially fatal pulmonary fibrosis. This risk is explicitly tied to the total cumulative lifetime dose administered, with a heightened chance of toxicity observed particularly with doses exceeding 400 units.

Classification Examples of Reactions
Very Common Fever, rigors, stomatitis (mouth sores), alopecia (hair loss), skin hyperpigmentation, and erythema
System-Organ Class Respiratory, Thoracic, and Mediastinal Disorders; Skin and Subcutaneous Tissue Disorders; Gastrointestinal Disorders

Serious Adverse Reactions and Safety Constraints

The regulatory labels highlight several serious adverse reactions, including the risk of severe, acute idiosyncratic reactions (anaphylaxis-like, with symptoms such as hypotension and mental confusion) typically reported after the first or second dose in certain populations, such as those with lymphoma. Rare but documented vascular events include myocardial infarction and cerebrovascular accident.

Specific safety constraints are noted for certain populations and pre-existing conditions. Pulmonary toxicity is officially documented as more common in patients older than 70 years of age. Caution is required in patients with pre-existing renal or pulmonary function impairment due to the drug's excretion and primary toxicity profile. Furthermore, the official labeling notes that the chance of pulmonary toxicity is increased by smoking and by the administration of high oxygen concentrations during surgical procedures.

Overdose and Emergency Response

Overdose and when to seek help

Overdose of Bleocel (Bleomycin sulfate) may result in both acute and delayed toxicities, requiring strict adherence to regulatory guidance. Acute manifestations documented in official regulatory sources include systemic signs such as hypotension (low blood pressure), fever, tachycardia (increased heart rate), and manifestations of shock. In rare cases, severe vascular toxicities, including myocardial infarction or cerebral arteritis, have also been reported. The use of the medicinal product must be discontinued immediately upon any suspicion of over-exposure, and immediate medical attention should be sought for any severe systemic or respiratory symptoms, such as sudden chest pain or difficulty breathing.


The most serious outcome officially recognized is pulmonary toxicity, which can progress to pulmonary fibrosis and carries a potential for death. This risk is dose-related, being strikingly increased when the total cumulative dose exceeds 400,000 IU (400 units). Furthermore, the risk of toxic reactions is documented as greater in patients with impaired renal function and in individuals over 70 years of age. Management for over-exposure is strictly symptomatic and supportive, as official regulatory documentation confirms that no specific antidote is known. Due to the risk of pulmonary damage, the use of high oxygen concentrations should be approached with caution.

Therapeutic Uses of Bleocel

What Bleocel Treats: Main Uses and Benefits

Bleocel (Bleomycin) is a specialized prescription medicine used in the management of specific cancers and the palliative treatment of a severe cancer complication. Its use is relevant in clinical settings that involve acute or unstable symptom patterns caused by malignant conditions. The drug may be part of symptomatic management in several key areas.


Therapeutic Scope and Benefits

Bleocel is commonly utilized as a foundational component in multi-drug regimens for conditions characterized by periods of heightened symptoms associated with aggressive cell growth. It is considered relevant for managing malignancies, including Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Testicular Carcinoma, and Squamous Cell Carcinomas of the head and neck, cervix, and external genitalia. The therapy is generally used to help with managing symptom clusters related to proliferation, and commonly contributes to easing the overall symptom load associated with these conditions.

Bleocel is also relevant for easing discomfort related to fluid accumulation to manage Malignant Pleural Effusion, a severe, recurring complication. This supports patients by assisting with maintaining functional stability when symptoms interfere with routine activities.


Quick Fact

Property Description
Quick Fact: Relevant for Systemic and Localized Symptom Burden
Primary Indication Types Lymphomas, Germ Cell Tumors, Squamous Cell Carcinomas
Specific Complication Use Management of Malignant Pleural Effusion
Main Patient Benefit Assists with maintaining functional stability and easing the overall symptom load

Regulatory References

  1. Bleomycin - DailyMed

Eligibility and Restrictions for Use

The official regulatory profile for Bleocel (Bleomycin sulfate) defines strict population eligibility rules, primarily based on avoiding severe pulmonary toxicity and hypersensitivity. The medicine is contraindicated and must not be used in patients with a history of hypersensitivity or an idiosyncratic reaction to Bleomycin. Absolute prohibition also applies to patients with severely impaired lung function, an acute pulmonary infection, or documented Bleomycin-induced lung damage from prior treatment.

Use is also contraindicated during pregnancy and lactation, as the drug can cause fetal harm, and women of childbearing potential are advised to avoid pregnancy for up to six months after therapy. Specific restrictions apply to patients with significant renal impairment (creatinine clearance less than 50 mL/min) and those with hepatic dysfunction, requiring extreme caution and monitoring. Pulmonary toxicity risk is increased in elderly patients (over 70 years) and those with a history of chest irradiation. Use in the pediatric population is generally not established due to insufficient experience cited by regulatory authorities.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes the officially documented interaction patterns of Bleocel (Bleomycin sulfate) as defined by government regulatory agencies.

Formal Restrictions and Contraindicated Combinations

Co-administration of Brentuximab Vedotin is generally not recommended and is considered a formally contraindicated combination due to the documented heightened risk of pulmonary toxicity.


Exposure-Modifying and Pharmacodynamic Interactions

Interaction Type Interacting Substance/Condition Regulatory Outcome
Exposure Alteration Nephrotoxic Agents (e.g., Cisplatin) Agents that impair renal function can reduce Bleocel clearance, leading to increased systemic exposure and the potential for enhanced toxicity.
Synergistic Toxicity Oxygen (High Concentration) Administration of high-concentration oxygen during anesthesia or surgery is associated with an increased risk and severity of pulmonary toxicity in previously treated patients.
Synergistic Toxicity Other Antineoplastic Agents Concurrent use, particularly with thoracic radiation, may result in toxicities occurring at lower cumulative doses, amplifying the pulmonary risk.
Effect on Co-drug Phenytoin / Fosphenytoin Bleocel co-administration results in decreased serum concentrations of these agents.

Population-Specific Interaction Notes

The risk of adverse reactions due to altered clearance is significantly greater in patients with impaired renal function. Since Bleocel is substantially cleared by the kidney, renal dysfunction delays elimination. Regulatory information also notes that advanced age (over 70 years) is a population-specific factor associated with an increased risk of pulmonary toxicity.

Mechanism of Action

The Oxidative Cleavage of DNA

The foundational mechanism of Bleocel is the formation of a highly reactive complex with Ferrous Iron ( Fe^2+) that, in the presence of Molecular Oxygen ( O2), generates Reactive Oxygen Species (ROS). These radicals physically cleave the backbone of the DNA double helix, causing extensive strand breaks. This direct molecular damage initiates a cellular cascade that results in the suppression of proliferation.

G2 Cell Cycle Arrest and Apoptosis

The irreparable nature of the DNA strand breaks activates the DNA Damage Response (DDR) pathway, triggering the crucial cellular failsafe known as G2-phase arrest. This mechanism physically prevents rapidly dividing cells from progressing into mitosis, ultimately compelling the damaged cells into apoptosis (programmed cell death). This process of induced cellular destruction is the core physiological consequence resulting from the molecule's mechanism.

️ Constraints by Bleomycin Hydrolase

The drug's activity is significantly constrained in most normal tissues by the enzyme Bleomycin Hydrolase, which hydrolyzes and inactivates the molecule. This enzymatic difference allows the active drug to persist and concentrate in tissues that naturally express low levels of the enzyme, such as the lungs and skin, thus defining the specific tissue areas where the mechanism's activity is sustained.

Dosage and Administration Information

Bleocel (Bleomycin Sulfate) is administered parenterally via intramuscular (IM), intravenous (IV), subcutaneous (SC), or intrapleural routes. Administration must be conducted under the supervision of a qualified physician experienced in oncologic therapies.

Official Dosing and Administration

Dosing Schedule: Initial dosing for various indications is typically 0.25 to 0.50 units/kg (or 10 to 20 units/m^2 body surface area) given weekly or twice weekly. For maintenance therapy in Hodgkin's disease, a dose of 1 unit daily or 5 units weekly IV or IM is specified after a significant therapeutic response. The total lifetime cumulative dose must not exceed 400 units due to the risk of dose-related pulmonary toxicity.

Preparation: Bleocel is supplied as a powder and must be reconstituted with an appropriate sterile diluent, such as 0.9% Sodium Chloride Injection, USP. Dextrose-containing diluents should not be used for reconstitution or dilution. The reconstituted solution is typically administered slowly over a period of 10 minutes for IV bolus or intra-arterial injection; fast bolus injections should be avoided.

Special Conditions:

  • Test Dose: Patients with lymphoma are required to receive a test dose of 2 units or less for the first one or two treatments due to the possibility of an anaphylactoid reaction. The full dose should only be given if no acute reaction occurs.
  • Renal Impairment: Dosing must be adjusted for patients with impaired renal function. For example, a patient with a creatinine clearance of 40 to 50 mL/min should receive approximately 70% of the normal dose.
  • Intrapleural Instillation: For malignant effusions, a dose of 60 units dissolved in 50 to 100 mL of saline is instilled after fluid drainage. The patient’s position must be changed multiple times over the subsequent hours to ensure uniform distribution.

Recent Clinical Evidence

Research evidence / Overview of studies for Bleocel

Bleocel was studied for specific malignant conditions in clinical research. The evidence base primarily consists of Randomized Controlled Trials (RCTs) and long-term observational cohort studies, which research examined the effect of Bleocel when used as part of multi-drug treatment regimens. Findings describe group patterns, and research provides context but not individual predictions.

Evidence for Use in Hodgkin Lymphoma

The research framework for Hodgkin Lymphoma is anchored by major Phase III randomized trials. Bleocel was evaluated in these studies across large populations of adults, and specialized analyses have explored outcomes in older adult groups. Researchers studied objective disease response rates and long-term survival measurements.

Studies monitored how disease status evolved in the observed populations, and reported on specific rates of remission and the proportion of patients who remained event-free over defined time intervals. Research consistently monitored pulmonary function outcomes; some studies involving older patients or higher total doses was associated with the incidence of respiratory issues.

Evidence for Use in Testicular Carcinoma and Germ Cell Tumors

Bleocel was evaluated in foundational Phase III randomized trials for managing testicular and other malignant germ cell tumors. The primary outcomes studied were long-term indicators of disease status, such as complete remission rates (CR) and Disease-Free Survival.

Findings describe patterns observed in these studies, including documented rates of complete remission (CR) across several trial populations. Data show patterns related to long-term event-free status when Bleocel was studied as part of the initial multi-drug combination. The research has extensively monitored pulmonary function changes and was observed in some studies to have temporary physiological imbalance in the lungs.

Evidence for Use in Malignant Pleural Effusion (MPE)

Bleocel was studied for the local management of Malignant Pleural Effusion (MPE). Research scenarios involved randomized trials that compared intrapleural administration of Bleocel to other available sclerosing agents. These studies monitored outcomes related to the success rate of pleurodesis and symptom control.

Comparative evidence suggests success rates were often observed to be similar to those of other agents commonly used for this palliative procedure; however, findings were mixed regarding specific comparisons of associated general complications.

What is Still Uncertain About Bleocel Research

While Bleocel has a well-defined role, evidence highlights what is known—and what is still uncertain. The main uncertainty relates to the long-term clinical meaning of the observed changes in pulmonary parameters, where long-term effects are not fully established across all age groups and cumulative doses. Quantifying the isolated contribution of Bleocel to the measured response remains a challenge in many trial designs. Study results reflect the specific conditions under which they were conducted.

Key Studies & References

  1. DailyMed: Bleomycin Sulfate for Injection, USP (Bleomycin Sulfate)
  2. NICE Guideline: Managing Lung Cancer and Malignant Pleural Effusion (Evidence for Pleurodesis)
  3. The role of bleomycin in the treatment of squamous cell carcinoma of the head and neck
  4. WHO Classification of Tumours: Female Genital Tract Tumours (Evidence Context for Cervix/Genitalia SCC)

Frequently Asked Questions (FAQ)

Common questions about Bleocel (FAQ)

Q: Is there a generic version of Bleocel available?

A: Yes, the product is available under the generic name Bleomycin Sulfate. The U.S. Food and Drug Administration (FDA) has approved generic versions of this medicine for use.


Q: Is Bleocel used for any conditions besides the ones listed on the official label?

A: Government-backed health resources mention that while regulatory labeling is restricted to approved uses, the drug may be used for other conditions as determined by a healthcare provider. This information acknowledges that use is not limited strictly to the primary malignant conditions listed on the official label.


Q: Is Bleocel considered a Schedule drug or controlled substance?

A: This medication is classified as a highly potent human prescription drug, specifically an antineoplastic antibiotic. According to U.S. government classification, it is not listed as a controlled substance or scheduled drug.


Q: Is Bleocel a new medicine or has it been around for a while?

A: The active ingredient, Bleomycin, is not considered a new medicine. It was discovered in 1962 and first approved for medical use in 1973.


Q: What does 'contraindicated' mean when official sources talk about Bleocel?

A: In medical and regulatory labeling, a contraindication means that the drug should not be used when a certain medical condition or history is present. The conditions listed as contraindications are those where the risk of the drug causing serious harm is judged to be unacceptably high.


Q: How long does Bleocel stay in your system after stopping?

A: According to the drug's pharmacokinetics data, in people with normal kidney function, the concentration of the drug in the blood typically decreases with a mean terminal half-life of approximately two hours following intravenous injection. The rate of elimination is dependent on kidney function.


Q: How quickly does Bleocel start working to address the treated condition?

A: Studies and official information indicate that for conditions such as lymphomas and testicular tumors, improvement is typically prompt and may be noted within two weeks. For squamous cell cancers, the response may occur more slowly, sometimes taking as long as three weeks.


Q: What are the general expectations about the duration of treatment with Bleocel?

A: According to official documents, treatment schedules can vary, continuing on consecutive weeks or at three-to-four-week intervals. A critical safety constraint noted in the prescribing information is the maximum total lifetime dose, which must not exceed 400 units due to the risk of dose-related pulmonary toxicity.


Q: Will Bleocel make me feel different right away?

A: Yes, some common effects, such as fever and chills, may occur within a few hours of administration. Furthermore, the official safety documentation notes that a rare but severe acute idiosyncratic reaction (anaphylaxis-like) may occur shortly after the first or second dose in certain patient populations.


Q: Can Bleocel be taken by older adults?

A: The official safety information notes that individuals over 70 years of age may be more sensitive to the effects of the medication. This population is specifically documented as having a heightened risk of developing lung problems. Therefore, the drug is used with caution in this population.


Q: Why do official sources list a certain medical history as a reason not to use Bleocel?

A: Official documents list certain medical histories as reasons not to use the drug because these conditions increase the risk of the drug's most serious side effects. For example, pre-existing pulmonary or renal impairment can amplify the risk of pulmonary fibrosis or lead to delayed drug elimination.


Q: Do you have to take Bleocel at a specific time of day?

A: The official prescribing information indicates that this medication is administered as an injection (IV, IM, SC, or intrapleural) in a supervised clinical setting. Since the schedule is typically weekly or twice weekly, the drug is not a self-administered pill that must be taken at a fixed time of day.


Q: Does Bleocel cause weight gain?

A: According to official product information, loss of appetite (anorexia) and weight loss are listed as common side effects associated with this medication. Weight gain is generally not listed as a known or expected adverse reaction in the regulatory documents.


Q: Is it normal to feel a change in appetite after starting Bleocel?

A: Yes, a loss of appetite, also known as anorexia, is officially documented as a common side effect of this medication. This finding is consistent with what is reported in the adverse reactions section of the prescribing information.


Q: Is Bleocel known to cause headaches?

A: Yes, headache is listed in external official resources as a reported side effect of the medication.


Q: Why do some people experience mild fatigue with Bleocel?

A: Fatigue is a side effect that is commonly reported by people receiving this medicine. However, the official product labeling does not specify the underlying biological or physiological reason why this experience occurs.


Q: Is Bleocel known to affect sleep patterns?

A: Sleep-related problems are not listed as a primary side effect in the regulatory documentation. However, very common side effects such as fever and chills typically occur within hours of administration and may affect comfort or sleep quality.


Q: Can Bleocel affect the results of blood tests?

A: Yes, the drug's mechanism of action and clearance require specific monitoring. The need to adjust the dose based on kidney function and the potential for hepatic or renal toxicity means that blood tests measuring liver and kidney markers are necessary for monitoring the drug's effects.


Q: Does the efficacy of Bleocel change over time?

A: Official regulatory documents do not explicitly discuss a change in the drug's efficacy (or the development of tolerance) over a full treatment course. However, clinical information suggests that if no improvement is noted within two to three weeks for certain conditions, further improvement is unlikely to occur.


Q: Why is it important to tell my doctor about all my vitamins before starting Bleocel?

A: According to regulatory documents, this medicine is primarily removed from the body by the kidneys. While specific vitamins are not listed as drug interactions, healthcare providers need to review all products being used, as any substance that affects kidney function could potentially alter the drug's clearance or increase systemic exposure.


Q: Does Bleocel interact with common over-the-counter pain relievers?

A: The officially documented interaction sections do not explicitly name most common over-the-counter pain relievers. Regulatory information states that substances which impair kidney function can reduce the drug's clearance, potentially leading to increased systemic exposure. Certain specific substances that affect clearance, like Acetylsalicylic acid, may decrease the rate at which the body removes the drug.


Q: Can Bleocel be taken at the same time as other heart medications?

A: The official drug interaction list does not explicitly name general classes of 'heart medications' or cardiovascular drugs. The label does note rare but documented vascular events as a potential adverse reaction.


Q: Does Bleocel have any known interactions with herbal supplements?

A: The official interaction section does not explicitly name herbal supplements as a source of known interactions. The most important consideration is how the substance is cleared by the body, as its elimination relies heavily on the kidneys.


Q: Does alcohol consumption affect how Bleocel works?

A: The official drug interaction list provided by regulatory authorities does not specify a known interaction between the drug and alcohol consumption.


Q: Are there any special foods or drinks to avoid while taking Bleocel?

A: No specific foods or beverages are explicitly listed in the official drug interaction information as being restricted or contraindicated. The label does not contain special dietary restrictions for general use.


Q: Why do the instructions mention avoiding grapefruit while using Bleocel?

A: The official prescribing information and interaction lists do not mention or mandate avoiding grapefruit while using this medication. This suggests no specific restriction is documented by the regulatory authority.


Q: Do I need to change my activities or diet while on Bleocel?

A: The official labeling explicitly notes that the risk of pulmonary (lung) toxicity is increased in people who smoke. Patients are advised to inform their healthcare team if they smoke. No other general activity or diet changes are explicitly mandated in the label's safety information.

How should Bleocel be stored and disposed of?

How to Store and Dispose of Bleocel

Bleocel (bleomycin sulfate) is a cytotoxic powder that requires specific environmental conditions for stability and mandatory hazardous drug procedures for handling and disposal.


Storage Requirements

The unopened vial containing the sterile powder must be stored under refrigeration at a temperature between 2°C and 8°C (36°F and 46°F). The product must not be frozen. Vials should be kept tightly closed and protected from both light and moisture. After reconstitution with 0.9% Sodium Chloride for Injection, the solution is stable for 24 hours at room temperature.

Handling and Disposal

Bleocel is classified as a hazardous drug by regulatory authorities. The medicine must be stored out of the sight and reach of children and in an area accessible only to authorized personnel. Unused, expired product and related waste materials must be disposed of following local and federal regulations for antineoplastic agents, and must not be released into the environment or placed in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bleocel found in:

A-Z Index: